nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—CDKL3—cardiovascular system—nicotine dependence	0.0221	0.0644	CbGeAlD
Sorafenib—Hoarseness—Varenicline—nicotine dependence	0.0163	0.0466	CcSEcCtD
Sorafenib—Aphthous stomatitis—Varenicline—nicotine dependence	0.0153	0.0437	CcSEcCtD
Sorafenib—Transient ischaemic attack—Varenicline—nicotine dependence	0.0142	0.0406	CcSEcCtD
Sorafenib—Suicide—Varenicline—nicotine dependence	0.0138	0.0395	CcSEcCtD
Sorafenib—Completed suicide—Varenicline—nicotine dependence	0.0122	0.0348	CcSEcCtD
Sorafenib—CDKL3—brain—nicotine dependence	0.0108	0.0316	CbGeAlD
Sorafenib—CDKL2—brain—nicotine dependence	0.00991	0.0289	CbGeAlD
Sorafenib—ZAK—cardiovascular system—nicotine dependence	0.00917	0.0267	CbGeAlD
Sorafenib—HIPK3—cardiovascular system—nicotine dependence	0.00897	0.0262	CbGeAlD
Sorafenib—MAPK15—brain—nicotine dependence	0.00893	0.026	CbGeAlD
Sorafenib—Rhinorrhoea—Varenicline—nicotine dependence	0.00884	0.0253	CcSEcCtD
Sorafenib—Dysphonia—Varenicline—nicotine dependence	0.0087	0.0249	CcSEcCtD
Sorafenib—Endocrine disorder—Varenicline—nicotine dependence	0.00864	0.0247	CcSEcCtD
Sorafenib—TIE1—cardiovascular system—nicotine dependence	0.00839	0.0245	CbGeAlD
Sorafenib—Gastrooesophageal reflux disease—Varenicline—nicotine dependence	0.00793	0.0227	CcSEcCtD
Sorafenib—FLT3—cardiovascular system—nicotine dependence	0.00763	0.0223	CbGeAlD
Sorafenib—Blood pressure increased—Varenicline—nicotine dependence	0.00716	0.0205	CcSEcCtD
Sorafenib—Influenza like illness—Varenicline—nicotine dependence	0.00695	0.0199	CcSEcCtD
Sorafenib—FLT4—cardiovascular system—nicotine dependence	0.00693	0.0202	CbGeAlD
Sorafenib—Mouth ulceration—Varenicline—nicotine dependence	0.00647	0.0185	CcSEcCtD
Sorafenib—BRAF—midbrain—nicotine dependence	0.00628	0.0183	CbGeAlD
Sorafenib—MKNK2—cardiovascular system—nicotine dependence	0.00627	0.0183	CbGeAlD
Sorafenib—MKNK1—cardiovascular system—nicotine dependence	0.00619	0.0181	CbGeAlD
Sorafenib—HIPK4—brain—nicotine dependence	0.00601	0.0175	CbGeAlD
Sorafenib—Eczema—Varenicline—nicotine dependence	0.00578	0.0165	CcSEcCtD
Sorafenib—RALBP1—cardiovascular system—nicotine dependence	0.00567	0.0165	CbGeAlD
Sorafenib—Renal failure acute—Varenicline—nicotine dependence	0.00563	0.0161	CcSEcCtD
Sorafenib—FLT1—cardiovascular system—nicotine dependence	0.00539	0.0157	CbGeAlD
Sorafenib—RAF1—cardiovascular system—nicotine dependence	0.00536	0.0156	CbGeAlD
Sorafenib—FGFR1—midbrain—nicotine dependence	0.00534	0.0156	CbGeAlD
Sorafenib—MAPK11—brain—nicotine dependence	0.00529	0.0154	CbGeAlD
Sorafenib—CDK7—brain—nicotine dependence	0.00521	0.0152	CbGeAlD
Sorafenib—TAOK2—brain—nicotine dependence	0.00517	0.0151	CbGeAlD
Sorafenib—AURKC—brain—nicotine dependence	0.00513	0.0149	CbGeAlD
Sorafenib—STK10—cardiovascular system—nicotine dependence	0.0051	0.0149	CbGeAlD
Sorafenib—MAP3K7—midbrain—nicotine dependence	0.00506	0.0147	CbGeAlD
Sorafenib—PDGFRA—cardiovascular system—nicotine dependence	0.00505	0.0147	CbGeAlD
Sorafenib—Mood swings—Varenicline—nicotine dependence	0.00492	0.0141	CcSEcCtD
Sorafenib—MKNK2—midbrain—nicotine dependence	0.0049	0.0143	CbGeAlD
Sorafenib—MKNK1—midbrain—nicotine dependence	0.00484	0.0141	CbGeAlD
Sorafenib—RET—midbrain—nicotine dependence	0.00478	0.0139	CbGeAlD
Sorafenib—Dry skin—Varenicline—nicotine dependence	0.00476	0.0136	CcSEcCtD
Sorafenib—EPHA6—brain—nicotine dependence	0.00475	0.0138	CbGeAlD
Sorafenib—Abdominal pain upper—Varenicline—nicotine dependence	0.00475	0.0136	CcSEcCtD
Sorafenib—Hypokalaemia—Varenicline—nicotine dependence	0.00473	0.0135	CcSEcCtD
Sorafenib—Breast disorder—Varenicline—nicotine dependence	0.0047	0.0134	CcSEcCtD
Sorafenib—Nasopharyngitis—Varenicline—nicotine dependence	0.00465	0.0133	CcSEcCtD
Sorafenib—Gastritis—Varenicline—nicotine dependence	0.0046	0.0132	CcSEcCtD
Sorafenib—KDR—cardiovascular system—nicotine dependence	0.00456	0.0133	CbGeAlD
Sorafenib—MAP2K5—cardiovascular system—nicotine dependence	0.00456	0.0133	CbGeAlD
Sorafenib—ZAK—brain—nicotine dependence	0.0045	0.0131	CbGeAlD
Sorafenib—Dysphagia—Varenicline—nicotine dependence	0.00449	0.0128	CcSEcCtD
Sorafenib—CSF1R—cardiovascular system—nicotine dependence	0.00445	0.013	CbGeAlD
Sorafenib—RALBP1—midbrain—nicotine dependence	0.00442	0.0129	CbGeAlD
Sorafenib—HIPK3—brain—nicotine dependence	0.0044	0.0128	CbGeAlD
Sorafenib—MAP3K19—brain—nicotine dependence	0.00431	0.0126	CbGeAlD
Sorafenib—Abdominal discomfort—Varenicline—nicotine dependence	0.00431	0.0123	CcSEcCtD
Sorafenib—FLT1—midbrain—nicotine dependence	0.00421	0.0123	CbGeAlD
Sorafenib—RAF1—midbrain—nicotine dependence	0.00418	0.0122	CbGeAlD
Sorafenib—EPHB6—midbrain—nicotine dependence	0.00416	0.0121	CbGeAlD
Sorafenib—Erectile dysfunction—Varenicline—nicotine dependence	0.00414	0.0118	CcSEcCtD
Sorafenib—TIE1—brain—nicotine dependence	0.00412	0.012	CbGeAlD
Sorafenib—KIT—cardiovascular system—nicotine dependence	0.00404	0.0118	CbGeAlD
Sorafenib—Infestation NOS—Varenicline—nicotine dependence	0.00401	0.0115	CcSEcCtD
Sorafenib—Infestation—Varenicline—nicotine dependence	0.00401	0.0115	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Varenicline—nicotine dependence	0.00397	0.0114	CcSEcCtD
Sorafenib—Acute coronary syndrome—Varenicline—nicotine dependence	0.00395	0.0113	CcSEcCtD
Sorafenib—BRAF—brain—nicotine dependence	0.00395	0.0115	CbGeAlD
Sorafenib—PDGFRB—cardiovascular system—nicotine dependence	0.00394	0.0115	CbGeAlD
Sorafenib—Myocardial infarction—Varenicline—nicotine dependence	0.00393	0.0112	CcSEcCtD
Sorafenib—Stomatitis—Varenicline—nicotine dependence	0.0039	0.0112	CcSEcCtD
Sorafenib—Hepatobiliary disease—Varenicline—nicotine dependence	0.00379	0.0108	CcSEcCtD
Sorafenib—Epistaxis—Varenicline—nicotine dependence	0.00378	0.0108	CcSEcCtD
Sorafenib—EPHX2—brain—nicotine dependence	0.00377	0.011	CbGeAlD
Sorafenib—KDR—midbrain—nicotine dependence	0.00356	0.0104	CbGeAlD
Sorafenib—MAP2K5—midbrain—nicotine dependence	0.00356	0.0104	CbGeAlD
Sorafenib—Urinary tract disorder—Varenicline—nicotine dependence	0.00355	0.0102	CcSEcCtD
Sorafenib—Connective tissue disorder—Varenicline—nicotine dependence	0.00353	0.0101	CcSEcCtD
Sorafenib—Urethral disorder—Varenicline—nicotine dependence	0.00352	0.0101	CcSEcCtD
Sorafenib—CSF1R—midbrain—nicotine dependence	0.00347	0.0101	CbGeAlD
Sorafenib—FLT4—brain—nicotine dependence	0.0034	0.00992	CbGeAlD
Sorafenib—Erythema multiforme—Varenicline—nicotine dependence	0.0034	0.00972	CcSEcCtD
Sorafenib—FGFR1—brain—nicotine dependence	0.00336	0.00978	CbGeAlD
Sorafenib—Tinnitus—Varenicline—nicotine dependence	0.00335	0.00959	CcSEcCtD
Sorafenib—Cardiac disorder—Varenicline—nicotine dependence	0.00334	0.00955	CcSEcCtD
Sorafenib—Angiopathy—Varenicline—nicotine dependence	0.00326	0.00933	CcSEcCtD
Sorafenib—Immune system disorder—Varenicline—nicotine dependence	0.00325	0.00929	CcSEcCtD
Sorafenib—Mediastinal disorder—Varenicline—nicotine dependence	0.00324	0.00927	CcSEcCtD
Sorafenib—Arrhythmia—Varenicline—nicotine dependence	0.00321	0.00919	CcSEcCtD
Sorafenib—MAP3K7—brain—nicotine dependence	0.00318	0.00926	CbGeAlD
Sorafenib—KIT—midbrain—nicotine dependence	0.00315	0.00919	CbGeAlD
Sorafenib—Mental disorder—Varenicline—nicotine dependence	0.00315	0.00901	CcSEcCtD
Sorafenib—Erythema—Varenicline—nicotine dependence	0.00313	0.00895	CcSEcCtD
Sorafenib—Malnutrition—Varenicline—nicotine dependence	0.00313	0.00895	CcSEcCtD
Sorafenib—HTR2B—cardiovascular system—nicotine dependence	0.00312	0.00911	CbGeAlD
Sorafenib—PDGFRB—midbrain—nicotine dependence	0.00308	0.00898	CbGeAlD
Sorafenib—MKNK2—brain—nicotine dependence	0.00308	0.00898	CbGeAlD
Sorafenib—Dysgeusia—Varenicline—nicotine dependence	0.00307	0.00877	CcSEcCtD
Sorafenib—MKNK1—brain—nicotine dependence	0.00304	0.00886	CbGeAlD
Sorafenib—Muscle spasms—Varenicline—nicotine dependence	0.00301	0.00861	CcSEcCtD
Sorafenib—RET—brain—nicotine dependence	0.003	0.00876	CbGeAlD
Sorafenib—Anaemia—Varenicline—nicotine dependence	0.00289	0.00828	CcSEcCtD
Sorafenib—Angioedema—Varenicline—nicotine dependence	0.00286	0.00818	CcSEcCtD
Sorafenib—Syncope—Varenicline—nicotine dependence	0.00281	0.00803	CcSEcCtD
Sorafenib—RALBP1—brain—nicotine dependence	0.00278	0.00811	CbGeAlD
Sorafenib—Loss of consciousness—Varenicline—nicotine dependence	0.00275	0.00787	CcSEcCtD
Sorafenib—Cough—Varenicline—nicotine dependence	0.00273	0.00781	CcSEcCtD
Sorafenib—Hypertension—Varenicline—nicotine dependence	0.0027	0.00773	CcSEcCtD
Sorafenib—Myalgia—Varenicline—nicotine dependence	0.00266	0.00762	CcSEcCtD
Sorafenib—Arthralgia—Varenicline—nicotine dependence	0.00266	0.00762	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Varenicline—nicotine dependence	0.00265	0.00757	CcSEcCtD
Sorafenib—FLT1—brain—nicotine dependence	0.00264	0.00771	CbGeAlD
Sorafenib—RAF1—brain—nicotine dependence	0.00263	0.00767	CbGeAlD
Sorafenib—EPHB6—brain—nicotine dependence	0.00261	0.00762	CbGeAlD
Sorafenib—Dry mouth—Varenicline—nicotine dependence	0.00261	0.00745	CcSEcCtD
Sorafenib—HTR2C—midbrain—nicotine dependence	0.0026	0.00757	CbGeAlD
Sorafenib—Infection—Varenicline—nicotine dependence	0.00254	0.00726	CcSEcCtD
Sorafenib—Shock—Varenicline—nicotine dependence	0.00251	0.00719	CcSEcCtD
Sorafenib—Nervous system disorder—Varenicline—nicotine dependence	0.00251	0.00717	CcSEcCtD
Sorafenib—STK10—brain—nicotine dependence	0.0025	0.0073	CbGeAlD
Sorafenib—Thrombocytopenia—Varenicline—nicotine dependence	0.0025	0.00715	CcSEcCtD
Sorafenib—Skin disorder—Varenicline—nicotine dependence	0.00248	0.0071	CcSEcCtD
Sorafenib—PDGFRA—brain—nicotine dependence	0.00248	0.00723	CbGeAlD
Sorafenib—Anorexia—Varenicline—nicotine dependence	0.00244	0.00697	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Varenicline—nicotine dependence	0.00233	0.00666	CcSEcCtD
Sorafenib—Dyspnoea—Varenicline—nicotine dependence	0.00228	0.00651	CcSEcCtD
Sorafenib—Dyspepsia—Varenicline—nicotine dependence	0.00225	0.00643	CcSEcCtD
Sorafenib—KDR—brain—nicotine dependence	0.00224	0.00652	CbGeAlD
Sorafenib—MAP2K5—brain—nicotine dependence	0.00224	0.00652	CbGeAlD
Sorafenib—Decreased appetite—Varenicline—nicotine dependence	0.00222	0.00635	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Varenicline—nicotine dependence	0.00221	0.00631	CcSEcCtD
Sorafenib—Fatigue—Varenicline—nicotine dependence	0.0022	0.0063	CcSEcCtD
Sorafenib—Pain—Varenicline—nicotine dependence	0.00218	0.00625	CcSEcCtD
Sorafenib—Constipation—Varenicline—nicotine dependence	0.00218	0.00625	CcSEcCtD
Sorafenib—CSF1R—brain—nicotine dependence	0.00218	0.00636	CbGeAlD
Sorafenib—Gastrointestinal pain—Varenicline—nicotine dependence	0.00209	0.00598	CcSEcCtD
Sorafenib—CYP2B6—cardiovascular system—nicotine dependence	0.00204	0.00596	CbGeAlD
Sorafenib—Urticaria—Varenicline—nicotine dependence	0.00203	0.0058	CcSEcCtD
Sorafenib—CYP2C9—cardiovascular system—nicotine dependence	0.00202	0.0059	CbGeAlD
Sorafenib—Body temperature increased—Varenicline—nicotine dependence	0.00202	0.00578	CcSEcCtD
Sorafenib—Abdominal pain—Varenicline—nicotine dependence	0.00202	0.00578	CcSEcCtD
Sorafenib—KIT—brain—nicotine dependence	0.00198	0.00578	CbGeAlD
Sorafenib—PDGFRB—brain—nicotine dependence	0.00193	0.00564	CbGeAlD
Sorafenib—Hypersensitivity—Varenicline—nicotine dependence	0.00188	0.00538	CcSEcCtD
Sorafenib—Asthenia—Varenicline—nicotine dependence	0.00183	0.00524	CcSEcCtD
Sorafenib—Pruritus—Varenicline—nicotine dependence	0.00181	0.00517	CcSEcCtD
Sorafenib—Diarrhoea—Varenicline—nicotine dependence	0.00175	0.005	CcSEcCtD
Sorafenib—ABCG2—midbrain—nicotine dependence	0.00173	0.00505	CbGeAlD
Sorafenib—Dizziness—Varenicline—nicotine dependence	0.00169	0.00483	CcSEcCtD
Sorafenib—HTR2C—brain—nicotine dependence	0.00163	0.00476	CbGeAlD
Sorafenib—Vomiting—Varenicline—nicotine dependence	0.00162	0.00465	CcSEcCtD
Sorafenib—Rash—Varenicline—nicotine dependence	0.00161	0.00461	CcSEcCtD
Sorafenib—Dermatitis—Varenicline—nicotine dependence	0.00161	0.0046	CcSEcCtD
Sorafenib—Headache—Varenicline—nicotine dependence	0.0016	0.00458	CcSEcCtD
Sorafenib—ABCC4—brain—nicotine dependence	0.00154	0.00449	CbGeAlD
Sorafenib—HTR2B—brain—nicotine dependence	0.00153	0.00447	CbGeAlD
Sorafenib—Nausea—Varenicline—nicotine dependence	0.00152	0.00434	CcSEcCtD
Sorafenib—CYP2C8—brain—nicotine dependence	0.00112	0.00326	CbGeAlD
Sorafenib—ABCB1—cardiovascular system—nicotine dependence	0.00109	0.00319	CbGeAlD
Sorafenib—ABCG2—brain—nicotine dependence	0.00109	0.00317	CbGeAlD
Sorafenib—CYP2B6—brain—nicotine dependence	0.001	0.00293	CbGeAlD
Sorafenib—ABCB1—midbrain—nicotine dependence	0.000853	0.00249	CbGeAlD
Sorafenib—BRAF—Transmission across Chemical Synapses—CHRNB2—nicotine dependence	0.000781	0.00254	CbGpPWpGaD
Sorafenib—RAF1—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.000777	0.00253	CbGpPWpGaD
Sorafenib—RAF1—Signaling by NGF—FGD1—nicotine dependence	0.000773	0.00251	CbGpPWpGaD
Sorafenib—RAF1—Transmission across Chemical Synapses—CHRNA5—nicotine dependence	0.000753	0.00245	CbGpPWpGaD
Sorafenib—HTR2B—GPCR ligand binding—TAS2R16—nicotine dependence	0.000746	0.00243	CbGpPWpGaD
Sorafenib—CYP2D6—brain—nicotine dependence	0.000746	0.00217	CbGeAlD
Sorafenib—RALBP1—Signaling Pathways—TAS2R16—nicotine dependence	0.000735	0.00239	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—TAS2R16—nicotine dependence	0.000723	0.00235	CbGpPWpGaD
Sorafenib—RAF1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNB2—nicotine dependence	0.000719	0.00234	CbGpPWpGaD
Sorafenib—BRAF—Transmission across Chemical Synapses—CHRNA4—nicotine dependence	0.000709	0.00231	CbGpPWpGaD
Sorafenib—BRAF—Neuronal System—CHRNA3—nicotine dependence	0.00068	0.00221	CbGpPWpGaD
Sorafenib—CYP1A2—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.000675	0.0022	CbGpPWpGaD
Sorafenib—RAF1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA4—nicotine dependence	0.000653	0.00212	CbGpPWpGaD
Sorafenib—CDK7—Gene Expression—CCAR1—nicotine dependence	0.000649	0.00211	CbGpPWpGaD
Sorafenib—RAF1—Neuronal System—GABRA4—nicotine dependence	0.000647	0.0021	CbGpPWpGaD
Sorafenib—CYP2B6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000646	0.0021	CbGpPWpGaD
Sorafenib—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.000643	0.00209	CbGpPWpGaD
Sorafenib—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.000634	0.00206	CbGpPWpGaD
Sorafenib—CYP3A5—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000632	0.00205	CbGpPWpGaD
Sorafenib—RAF1—Neuronal System—CHRNB4—nicotine dependence	0.00062	0.00202	CbGpPWpGaD
Sorafenib—RAF1—Transmission across Chemical Synapses—CHRNA3—nicotine dependence	0.000614	0.002	CbGpPWpGaD
Sorafenib—CYP2B6—Biological oxidations—CYP2A7—nicotine dependence	0.000609	0.00198	CbGpPWpGaD
Sorafenib—HTR2C—GPCR ligand binding—TAS2R16—nicotine dependence	0.000602	0.00196	CbGpPWpGaD
Sorafenib—CYP2B6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000601	0.00195	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—TAS2R16—nicotine dependence	0.000599	0.00195	CbGpPWpGaD
Sorafenib—BRAF—Neuronal System—CHRNB2—nicotine dependence	0.000598	0.00195	CbGpPWpGaD
Sorafenib—CYP3A5—Biological oxidations—CYP2A7—nicotine dependence	0.000595	0.00194	CbGpPWpGaD
Sorafenib—MKNK1—Disease—AKR1B10—nicotine dependence	0.000593	0.00193	CbGpPWpGaD
Sorafenib—CYP3A5—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000587	0.00191	CbGpPWpGaD
Sorafenib—RAF1—Neuronal System—CHRNA5—nicotine dependence	0.000577	0.00188	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—FGD1—nicotine dependence	0.000576	0.00187	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—FGD1—nicotine dependence	0.000567	0.00184	CbGpPWpGaD
Sorafenib—EPHX2—Metabolism—CYP2A7—nicotine dependence	0.000566	0.00184	CbGpPWpGaD
Sorafenib—CYP2C8—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000547	0.00178	CbGpPWpGaD
Sorafenib—BRAF—Neuronal System—CHRNA4—nicotine dependence	0.000543	0.00177	CbGpPWpGaD
Sorafenib—RAF1—Transmission across Chemical Synapses—CHRNB2—nicotine dependence	0.00054	0.00176	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—TAS2R16—nicotine dependence	0.000539	0.00175	CbGpPWpGaD
Sorafenib—ABCB1—brain—nicotine dependence	0.000536	0.00156	CbGeAlD
Sorafenib—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.000521	0.0017	CbGpPWpGaD
Sorafenib—CYP2C8—Biological oxidations—CYP2A7—nicotine dependence	0.000516	0.00168	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—AKR1B10—nicotine dependence	0.000509	0.00166	CbGpPWpGaD
Sorafenib—CYP2C8—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000509	0.00165	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—AKR1B10—nicotine dependence	0.000501	0.00163	CbGpPWpGaD
Sorafenib—RAF1—Transmission across Chemical Synapses—CHRNA4—nicotine dependence	0.000491	0.0016	CbGpPWpGaD
Sorafenib—CYP2C19—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000488	0.00159	CbGpPWpGaD
Sorafenib—HTR2B—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000482	0.00157	CbGpPWpGaD
Sorafenib—MAPK11—Gene Expression—CCAR1—nicotine dependence	0.000474	0.00154	CbGpPWpGaD
Sorafenib—RAF1—Neuronal System—CHRNA3—nicotine dependence	0.00047	0.00153	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—FGD1—nicotine dependence	0.00047	0.00153	CbGpPWpGaD
Sorafenib—CYP2C19—Biological oxidations—CYP2A7—nicotine dependence	0.00046	0.0015	CbGpPWpGaD
Sorafenib—CYP2C19—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000454	0.00148	CbGpPWpGaD
Sorafenib—CYP2D6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000449	0.00146	CbGpPWpGaD
Sorafenib—CYP2C9—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000445	0.00145	CbGpPWpGaD
Sorafenib—CYP2D6—Biological oxidations—CYP2A7—nicotine dependence	0.000423	0.00138	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—FGD1—nicotine dependence	0.000423	0.00138	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000422	0.00137	CbGpPWpGaD
Sorafenib—CYP2C9—Biological oxidations—CYP2A7—nicotine dependence	0.00042	0.00137	CbGpPWpGaD
Sorafenib—CDK7—Disease—AKR1B10—nicotine dependence	0.000418	0.00136	CbGpPWpGaD
Sorafenib—CYP2D6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000418	0.00136	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—AKR1B10—nicotine dependence	0.000415	0.00135	CbGpPWpGaD
Sorafenib—CYP2C9—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000414	0.00135	CbGpPWpGaD
Sorafenib—RAF1—Neuronal System—CHRNB2—nicotine dependence	0.000414	0.00135	CbGpPWpGaD
Sorafenib—ABCC4—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000414	0.00135	CbGpPWpGaD
Sorafenib—HTR2B—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000413	0.00134	CbGpPWpGaD
Sorafenib—MAPK11—Innate Immune System—WASF2—nicotine dependence	0.0004	0.0013	CbGpPWpGaD
Sorafenib—HTR2C—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000389	0.00127	CbGpPWpGaD
Sorafenib—MAPK11—Innate Immune System—WASF1—nicotine dependence	0.000384	0.00125	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—TAS2R16—nicotine dependence	0.000383	0.00125	CbGpPWpGaD
Sorafenib—CYP1A2—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000381	0.00124	CbGpPWpGaD
Sorafenib—RAF1—Neuronal System—CHRNA4—nicotine dependence	0.000376	0.00122	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—AKR1B10—nicotine dependence	0.000374	0.00122	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TAS2R16—nicotine dependence	0.000368	0.0012	CbGpPWpGaD
Sorafenib—KIT—Innate Immune System—WASF2—nicotine dependence	0.000361	0.00117	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—WASF2—nicotine dependence	0.000361	0.00117	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TAS2R16—nicotine dependence	0.000359	0.00117	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—WASF2—nicotine dependence	0.000359	0.00117	CbGpPWpGaD
Sorafenib—CYP1A2—Biological oxidations—CYP2A7—nicotine dependence	0.000359	0.00117	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—TAS2R16—nicotine dependence	0.000358	0.00116	CbGpPWpGaD
Sorafenib—CYP1A2—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000354	0.00115	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—WASF2—nicotine dependence	0.000353	0.00115	CbGpPWpGaD
Sorafenib—ABCC2—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000349	0.00113	CbGpPWpGaD
Sorafenib—HTR2B—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000349	0.00113	CbGpPWpGaD
Sorafenib—RAF1—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000348	0.00113	CbGpPWpGaD
Sorafenib—KIT—Innate Immune System—WASF1—nicotine dependence	0.000346	0.00112	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—WASF1—nicotine dependence	0.000346	0.00112	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—WASF1—nicotine dependence	0.000344	0.00112	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—WASF2—nicotine dependence	0.000342	0.00111	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—WASF2—nicotine dependence	0.000341	0.00111	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00034	0.00111	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—WASF1—nicotine dependence	0.000338	0.0011	CbGpPWpGaD
Sorafenib—HTR2C—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000333	0.00108	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—FGD1—nicotine dependence	0.000331	0.00108	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—WASF1—nicotine dependence	0.000328	0.00107	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—WASF1—nicotine dependence	0.000327	0.00106	CbGpPWpGaD
Sorafenib—HTR2B—GPCR ligand binding—OPRM1—nicotine dependence	0.000315	0.00102	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—OPRM1—nicotine dependence	0.00031	0.00101	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—TAS2R16—nicotine dependence	0.000309	0.001	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TAS2R16—nicotine dependence	0.000309	0.001	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—WASF2—nicotine dependence	0.000308	0.001	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TAS2R16—nicotine dependence	0.000306	0.000994	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—OPRM1—nicotine dependence	0.000305	0.000991	CbGpPWpGaD
Sorafenib—ABCG2—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000303	0.000987	CbGpPWpGaD
Sorafenib—BRAF—Disease—AKR1B10—nicotine dependence	0.000303	0.000984	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—FGD1—nicotine dependence	0.000301	0.000977	CbGpPWpGaD
Sorafenib—HTR2B—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000299	0.000971	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—WASF1—nicotine dependence	0.000295	0.000959	CbGpPWpGaD
Sorafenib—CYP3A4—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000294	0.000955	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—WASF2—nicotine dependence	0.000292	0.000951	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—FGD1—nicotine dependence	0.000289	0.00094	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—FGD1—nicotine dependence	0.000282	0.000916	CbGpPWpGaD
Sorafenib—HTR2C—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000281	0.000915	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—FGD1—nicotine dependence	0.000281	0.000914	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—WASF1—nicotine dependence	0.00028	0.000912	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TAS2R16—nicotine dependence	0.000278	0.000905	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TAS2R16—nicotine dependence	0.000278	0.000905	CbGpPWpGaD
Sorafenib—CYP3A4—Biological oxidations—CYP2A7—nicotine dependence	0.000277	0.0009	CbGpPWpGaD
Sorafenib—KIT—Disease—AKR1B10—nicotine dependence	0.000275	0.000896	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—WASF2—nicotine dependence	0.000274	0.000892	CbGpPWpGaD
Sorafenib—CYP3A4—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000273	0.000888	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—FGD1—nicotine dependence	0.000267	0.000868	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TAS2R16—nicotine dependence	0.000264	0.000859	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TAS2R16—nicotine dependence	0.000263	0.000856	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—WASF2—nicotine dependence	0.000263	0.000856	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—WASF1—nicotine dependence	0.000263	0.000855	CbGpPWpGaD
Sorafenib—FGFR1—Disease—AKR1B10—nicotine dependence	0.000261	0.00085	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—AKR1B10—nicotine dependence	0.000261	0.000848	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—AKR1B10—nicotine dependence	0.000255	0.00083	CbGpPWpGaD
Sorafenib—HTR2C—GPCR ligand binding—OPRM1—nicotine dependence	0.000254	0.000826	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—OPRM1—nicotine dependence	0.000252	0.000821	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—WASF1—nicotine dependence	0.000252	0.000821	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—AKR1B10—nicotine dependence	0.000249	0.000809	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—FGD1—nicotine dependence	0.000242	0.000789	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—FGD1—nicotine dependence	0.000242	0.000787	CbGpPWpGaD
Sorafenib—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000241	0.000784	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—FGD1—nicotine dependence	0.00024	0.00078	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TAS2R16—nicotine dependence	0.000237	0.000772	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—AKR1B10—nicotine dependence	0.000235	0.000764	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—WASF2—nicotine dependence	0.000233	0.000758	CbGpPWpGaD
Sorafenib—HTR2B—GPCR ligand binding—DRD2—nicotine dependence	0.000227	0.00074	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—OPRM1—nicotine dependence	0.000227	0.000739	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TAS2R16—nicotine dependence	0.000226	0.000736	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—DRD2—nicotine dependence	0.000224	0.000728	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—WASF1—nicotine dependence	0.000223	0.000727	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—DRD2—nicotine dependence	0.00022	0.000716	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—FGD1—nicotine dependence	0.000218	0.00071	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—FGD1—nicotine dependence	0.000218	0.00071	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—AKR1B10—nicotine dependence	0.000214	0.000696	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—AKR1B10—nicotine dependence	0.000212	0.000689	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TAS2R16—nicotine dependence	0.000211	0.000688	CbGpPWpGaD
Sorafenib—KIT—Immune System—WASF2—nicotine dependence	0.00021	0.000683	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—WASF2—nicotine dependence	0.00021	0.000683	CbGpPWpGaD
Sorafenib—RAF1—Disease—AKR1B10—nicotine dependence	0.000209	0.000681	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—FGD1—nicotine dependence	0.000207	0.000674	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—FGD1—nicotine dependence	0.000207	0.000672	CbGpPWpGaD
Sorafenib—KIT—Immune System—WASF1—nicotine dependence	0.000201	0.000655	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—WASF1—nicotine dependence	0.000201	0.000655	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—WASF2—nicotine dependence	0.000199	0.000649	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—WASF2—nicotine dependence	0.000199	0.000647	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—AKR1B10—nicotine dependence	0.000193	0.000627	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—AKR1B10—nicotine dependence	0.000193	0.000627	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—WASF1—nicotine dependence	0.000191	0.000622	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—WASF1—nicotine dependence	0.000191	0.00062	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—FGD1—nicotine dependence	0.000186	0.000605	CbGpPWpGaD
Sorafenib—HTR2C—GPCR ligand binding—DRD2—nicotine dependence	0.000184	0.000597	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—AKR1B10—nicotine dependence	0.000183	0.000595	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—AKR1B10—nicotine dependence	0.000183	0.000594	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TAS2R16—nicotine dependence	0.000183	0.000594	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—DRD2—nicotine dependence	0.000183	0.000594	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—WASF2—nicotine dependence	0.00018	0.000585	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—WASF2—nicotine dependence	0.000179	0.000583	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—OPRM1—nicotine dependence	0.000178	0.000578	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—FGD1—nicotine dependence	0.000178	0.000577	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—WASF2—nicotine dependence	0.000175	0.00057	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—WASF1—nicotine dependence	0.000172	0.000561	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—WASF1—nicotine dependence	0.000172	0.000559	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—WASF1—nicotine dependence	0.000168	0.000546	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—CYP2A7—nicotine dependence	0.000168	0.000545	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—CYP2A7—nicotine dependence	0.000168	0.000545	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—FGD1—nicotine dependence	0.000166	0.00054	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—AKR1B10—nicotine dependence	0.000164	0.000535	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—DRD2—nicotine dependence	0.000164	0.000535	CbGpPWpGaD
Sorafenib—ABCB1—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000164	0.000534	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—OPRM1—nicotine dependence	0.000161	0.000525	CbGpPWpGaD
Sorafenib—RAF1—Immune System—WASF2—nicotine dependence	0.00016	0.000519	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—AKR1B10—nicotine dependence	0.000157	0.00051	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—OPRM1—nicotine dependence	0.000155	0.000505	CbGpPWpGaD
Sorafenib—RAF1—Immune System—WASF1—nicotine dependence	0.000153	0.000498	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—OPRM1—nicotine dependence	0.000151	0.000492	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—OPRM1—nicotine dependence	0.000151	0.000491	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—WASF2—nicotine dependence	0.000151	0.00049	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—WASF2—nicotine dependence	0.000149	0.000485	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—AKR1B10—nicotine dependence	0.000147	0.000477	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—WASF1—nicotine dependence	0.000144	0.00047	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—OPRM1—nicotine dependence	0.000143	0.000467	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—FGD1—nicotine dependence	0.000143	0.000466	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—WASF1—nicotine dependence	0.000143	0.000465	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—CYP2A7—nicotine dependence	0.000142	0.000462	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—CYP2A7—nicotine dependence	0.000141	0.000458	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—WASF2—nicotine dependence	0.000136	0.000442	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—WASF2—nicotine dependence	0.000136	0.000442	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—OPRM1—nicotine dependence	0.00013	0.000424	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—WASF1—nicotine dependence	0.00013	0.000424	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—WASF1—nicotine dependence	0.00013	0.000424	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—OPRM1—nicotine dependence	0.00013	0.000423	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—WASF2—nicotine dependence	0.000129	0.000419	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—OPRM1—nicotine dependence	0.000129	0.000419	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—WASF2—nicotine dependence	0.000129	0.000418	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—DRD2—nicotine dependence	0.000129	0.000418	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—AKR1B10—nicotine dependence	0.000127	0.000411	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—WASF1—nicotine dependence	0.000124	0.000402	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—WASF1—nicotine dependence	0.000123	0.000401	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—OPRM1—nicotine dependence	0.000117	0.000381	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—OPRM1—nicotine dependence	0.000117	0.000381	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—DRD2—nicotine dependence	0.000117	0.00038	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—WASF2—nicotine dependence	0.000116	0.000377	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—DRD2—nicotine dependence	0.000112	0.000365	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—OPRM1—nicotine dependence	0.000111	0.000362	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—WASF1—nicotine dependence	0.000111	0.000361	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—OPRM1—nicotine dependence	0.000111	0.000361	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—WASF2—nicotine dependence	0.00011	0.000359	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—DRD2—nicotine dependence	0.000109	0.000356	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—DRD2—nicotine dependence	0.000109	0.000355	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—WASF1—nicotine dependence	0.000106	0.000345	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—CYP2A7—nicotine dependence	0.000104	0.000339	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—DRD2—nicotine dependence	0.000104	0.000337	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—WASF2—nicotine dependence	0.000103	0.000336	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—CYP2A7—nicotine dependence	0.000102	0.000331	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—OPRM1—nicotine dependence	0.0001	0.000325	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—WASF1—nicotine dependence	9.9e-05	0.000322	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—OPRM1—nicotine dependence	9.54e-05	0.00031	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—DRD2—nicotine dependence	9.42e-05	0.000306	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—DRD2—nicotine dependence	9.4e-05	0.000306	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—DRD2—nicotine dependence	9.31e-05	0.000303	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—WASF2—nicotine dependence	8.91e-05	0.00029	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—OPRM1—nicotine dependence	8.91e-05	0.00029	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CYP2A7—nicotine dependence	8.82e-05	0.000287	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—WASF1—nicotine dependence	8.55e-05	0.000278	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—DRD2—nicotine dependence	8.48e-05	0.000276	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—DRD2—nicotine dependence	8.48e-05	0.000276	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—DRD2—nicotine dependence	8.05e-05	0.000262	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—DRD2—nicotine dependence	8.03e-05	0.000261	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CYP2A7—nicotine dependence	7.87e-05	0.000256	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—OPRM1—nicotine dependence	7.69e-05	0.00025	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CYP2A7—nicotine dependence	7.68e-05	0.00025	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CYP2A7—nicotine dependence	7.24e-05	0.000236	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—DRD2—nicotine dependence	7.23e-05	0.000235	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CYP2A7—nicotine dependence	7.18e-05	0.000233	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—DRD2—nicotine dependence	6.9e-05	0.000224	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—DRD2—nicotine dependence	6.44e-05	0.00021	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CYP2A7—nicotine dependence	6.13e-05	0.0002	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—DRD2—nicotine dependence	5.56e-05	0.000181	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP2A7—nicotine dependence	4.73e-05	0.000154	CbGpPWpGaD
